

Brief Contents

Part 1: The Basics

- Chapter 1 General Pharmacologic Principles 3
- Chapter 2 The Metric System and Drug Dosage Calculations 39
- Chapter 3 Pharmacology of the Autonomic Nervous System 55
- Chapter 4 Medicated Aerosol Treatments 77

Part 2: The Specific Drug Categories

- Chapter 5 Bronchodilators 101
- Chapter 6 Mucokinetics and Surfactants 135
- Chapter 7 Anti-inflammatory and Antiasthmatic Agents 163
- Chapter 8 Antimicrobial Agents 191
- Chapter 9 Cardiac Agents 219
- Chapter 10 Blood Pressure and Antithrombotic Agents 247
- Chapter 11 Neuromuscular, Sedative, Anesthetic, and Analgesic Agents 277
- Chapter 12 Therapeutic Medical Gases 307

Part 3: Putting It All Together

- Chapter 13 Pharmacologic Management of Asthma, Chronic Bronchitis, and Emphysema 329
- Chapter 14 Pharmacologic Treatment of Respiratory Infectious Diseases 363
- Chapter 15 Medications for Emergency Cardiovascular Life Support 395

Appendices 421

Glossary 425

Index 433

Contents

Foreword	xv
Acknowledgments	xvi
Preface	xvii
Supplements and Resources	xix
Previous Editions' Reviewers	xxi

Part 1: The Basics 1

Chapter 1

General Pharmacologic Principles 3

1.1	Basic Terms	4
1.2	Drug Development	5
1.3	Herbal Supplements (Nutraceuticals)	6
1.4	Drug Information Sources	7
1.5	Interpreting Drug Information	8
1.5a	Drug Names	8
1.5b	Clinical Pharmacology	9
1.5c	Indications and Usage	10
1.5d	Contraindications	11
1.5e	Drug Interactions	12
1.5f	Adverse Drug Reactions	13
1.5g	Dosage and Administration	16
1.6	Routes of Administration	16
1.6a	Enteral Routes	18
1.6b	Parenteral Routes	18
1.6c	Other Routes	18
1.7	Pharmacokinetics	20
1.7a	Absorption	20
1.7b	Distribution	22
1.7c	Metabolism	23
1.7d	Elimination	24
1.8	Pharmacodynamics	25
1.8a	Selectivity	25
1.8b	Lock and Key Receptor Theory	26
1.8c	Racemic Mixtures	27
1.8d	Agonists versus Antagonists	27

1.8e	Potency	28
1.8f	Tolerance	29
1.8g	Half-Life	29
1.8h	Poisoning and Toxicity	30

1.9	Pharmacogenomics	30
1.10	Prescription Orders	31
1.11	Commonsense Rules	33
Summary		35
Review Questions		35
Case Study 1–1 Calvin Davis		37

Chapter 2

The Metric System and Drug Dosage Calculations 39

2.1	Exponential Powers of 10	41
2.1a	Exponents	41
2.2	Systems of Measurement	42
2.2a	United States Customary System	42
2.2b	The Metric System	42
2.2c	Conversion of Units	45
2.2d	Factor-Label Method to Convert between Systems	46
2.3	Drug Dosage Calculations	47
2.3a	Solutions	47
2.3b	Percentage Solutions	48
2.3c	Setting Up Proportions	49
2.3d	Ratio Solutions	51
2.3e	Drug Orders in Drops	51

Summary		53
Review Questions		53

Chapter 3

Pharmacology of the Autonomic Nervous System 55

- 3.1 Nervous System Divisions 56
 - 3.1a PNS Divisions 57
- 3.2 Nervous System Conduction 61
 - 3.2a Types and Location of Neurotransmitters 62
 - 3.2b Receptors 63
 - 3.2c Receptor Classification 65
- 3.3 ANS Drug Terminology 66
 - 3.3a Direct- and Indirect-Acting Agents 68
 - 3.3b Parasympathomimetics 68
 - 3.3c Parasympatholytics 70
 - 3.3d Sympathomimetics 71
 - 3.3e Sympatholytics 73

Summary 74

Review Questions 74

Case Study 3–1 Maria Ramirez 75

Chapter 4

Medicated Aerosol Treatments 77

- 4.1 Basic Concepts of Medicated Aerosols 78
 - 4.1a What Is Aerosol Therapy? 78
 - 4.1b Advantages and Disadvantages 79
 - 4.1c Technical Background 80
 - 4.1d Aerosol Size Matters 81
 - 4.1e Breathing Pattern 82
 - 4.1f Types of Aerosolized Drugs 83
- 4.2 Aerosol Delivery Devices 84
 - 4.2a Metered-Dose Inhaler 84
 - 4.2b Small-Volume Nebulizer 88
 - 4.2c Other Nebulizer Designs 89
 - 4.2d Continuous Bronchodilator Therapy 90
 - 4.2e Dry Powder Inhaler 90
 - 4.2f Choosing the Appropriate Delivery Device 92
 - 4.2g Aerosol Delivery in Intubated Patients 92
- 4.3 The Future 95

Summary 97

Review Questions 97

Case Study 4–1 Mr. Davidson 98

Part 2: The Specific Drug Categories 99

Chapter 5

Bronchodilators 101

- 5.1 Airway Anatomy and Physiology 102
 - 5.1a Bronchoconstriction versus Bronchospasm 103
- 5.2 Neurological Control of Bronchial Smooth Muscle 105
 - 5.2a Sympathetic Nervous System 105
 - 5.2b Parasympathetic Nervous System 105
 - 5.2c Chemical Mediators of Neural Transmission 106
 - 5.2d Sympathetic Nervous System Receptors 107
 - 5.2e The Sympathetic Nervous System in the Lung 108
- 5.3 Bronchodilators 109
 - 5.3a Sympathomimetic (Adrenergic) Bronchodilators 110
 - 5.3b Mechanism of Action 110
- 5.4 Development of the β -Agonists 111
 - 5.4a Catecholamines 112
 - 5.4b Resorcinols 113
 - 5.4c Saligenins 114
 - 5.4d Side Effects of β -Agonists 117
 - 5.4e Classification by Duration of Action 119
- 5.5 Anticholinergic (Parasympatholytic) Bronchodilators 122
 - 5.5a Mechanism of Action 122
 - 5.5b Atropine Sulfate 124
 - 5.5c Ipratropium Bromide (Atrovent®) 124
 - 5.5d Tiotropium Bromide (Spiriva®) 125
 - 5.5e Monitoring Outcomes of Inhaled Bronchodilator Therapy 128



- 5.6 Methylxanthines 129
 - 5.6a Mechanism of Action 129
 - 5.6b Nonbronchodilating Effects of Theophylline 129
- Summary 131
- Review Questions 131
- Case Study 5–1 A 66-year-old male 133
- Case Study 5–2 A 9-year-old boy 133
- Case Study 5–3 A patient with COPD 133

Chapter 6

Mucokinetics and Surfactants 135

- 6.1 The Mucociliary System 136
 - 6.1a Anatomy and Physiology 136
 - 6.1b Structure and Composition of Mucus 137
- 6.2 Bland Aerosols 141
 - 6.2a Definitions 141
 - 6.2b Delivery Methods 141
 - 6.2c Bland Solutions 143
- 6.3 Mucolytics 145
 - 6.3a Definition 145
 - 6.3b Expectorants 148
 - 6.3c Antitussives/Cough Suppressants 148
 - 6.3d Conclusion 149
- 6.4 Surface-Active Agents 150
 - 6.4a Alveolar Physiology and Surfactant Synthesis 150
 - 6.4b Surfactant Function 151
 - 6.4c Indications for Surfactant Replacement Therapy 154
 - 6.4d Types of Exogenous Surfactants 154
 - 6.4e Therapeutic Approaches 155
 - 6.4f Representative Drugs 155
 - 6.4g General Techniques of Surfactant Administration 156
 - 6.4h Adverse Reactions 157
 - 6.4i Surfactant Administration in Adult Patients 158

Summary 160

Review Questions 160

Case Study 6–1 A COPD patient 162

Case Study 6–2 A baby boy 162

Chapter 7

Anti-inflammatory and Antiasthmatic Agents 163

- 7.1 The Inflammatory Process 164
 - 7.1a The Immune Response 164
 - 7.1b Mast Cell Chemical Mediator Release 165
 - 7.1c Types of Asthma 167
 - 7.1d Phases of the Inflammatory Response 167
- 7.2 Corticosteroids 169
 - 7.2a Corticosteroid Physiology 169
 - 7.2b Hypothalamic-Pituitary-Adrenal Axis 171
 - 7.2c Corticosteroid Mechanism of Action 172
 - 7.2d Corticosteroid Use in Airway Remodeling 172
 - 7.2e Adverse Effects of Corticosteroids 173
 - 7.2f Oral and Parenteral Corticosteroid Administration 174
 - 7.2g Inhaled Corticosteroids 174
 - 7.2h Benefits of Daily Corticosteroid Use 177
 - 7.2i Steroid Dependency 179
- 7.3 Antiasthmatics 179
 - 7.3a Cromolyn Sodium 179
 - 7.3b Dosage Forms 180
 - 7.3c Side Effects 180
- 7.4 Prostaglandins 180
 - 7.4a Physiology 180
- 7.5 Leukotriene Modifiers 181
 - 7.5a Physiology 181
- 7.6 Antiasthmatic Monoclonal Antibody 182
 - 7.6a Physiology 182
- 7.7 Treating Upper Airway Congestion 182
 - 7.7a Allergic Rhinitis 182
 - 7.7b Intranasal Medications 183
 - 7.7c Antihistamines 184
 - 7.7d Decongestants 187

Summary	188
Review Questions	188
Case Study 7–1 A 24-year-old woman	189
Case Study 7–2 A 40-year-old man	189

Chapter 8

Antimicrobial Agents 191

8.1	General Principles of Anti-infective Therapy	192
8.1a	Terminology	192
8.1b	The Infection Process	193
8.1c	Empiric Therapy	193
8.1d	Classification of Bacteria	194
8.1e	Identification of Pathogenic Organisms	195
8.1f	Mechanisms of Resistance	198
8.1g	Monitoring Anti-infective Therapy	199
8.2	Classification of Antibacterial Agents	200
8.2a	Bacteriostatic versus Bactericidal	200
8.2b	Broad-Spectrum versus Narrow-Spectrum	200
8.2c	Based on Mechanism of Action	200
8.2d	Antibacterial Agents	201
8.3	Antivirals	209
8.3a	Antivirals to Treat Herpes	210
8.3b	Antivirals to Treat Influenza	210
8.3c	Antivirals to Treat COVID-19	211
8.3d	Antivirals to Treat Respiratory Syncytial Virus	211
8.3e	Antivirals to Treat Acquired Immunodeficiency Syndrome (AIDS)	213
8.4	Antifungals	214
	Summary	217
	Review Questions	217

Case Study 8–1 A 68-year-old man	218
Case Study 8–2 A 47-year-old woman	218

Chapter 9

Cardiac Agents 219

9.1	Cardiovascular Overview	221
9.1a	Basic Terminology	221
9.1b	Cardiac Circulation	221
9.1c	Cardiac Conduction	222
9.1d	Ion Influence	224
9.1e	The ECG Tracing	225
9.1f	Arrhythmias	226
9.1g	Sites of Arrhythmias	227
9.2	Antiarrhythmic Agents	227
9.2a	Therapeutic Goals	227
9.2b	Mechanism of Action	227
9.2c	Classification of Antiarrhythmic Drugs	227
9.3	Heart Failure	229
9.3a	Pathophysiology	229
9.3b	Drugs to Treat Heart Failure	230
9.3c	Digoxin for Heart Failure	231
9.3d	ACE Inhibitors for Heart Failure	231
9.3e	ARBs for Heart Failure	231
9.3f	Angiotensin Receptor Neprilysin Inhibitor	232
9.3g	β -Antagonists for Heart Failure	232
9.3h	Vasodilators for Heart Failure	232
9.3i	Diuretics for Heart Failure	233
9.3j	Aldosterone Antagonists for Heart Failure	234
9.3k	Intravenous Inotropes for Heart Failure	234
9.3l	Dopamine for Heart Failure	234
9.3m	Nitroprusside for Heart Failure	234
9.3n	Nitroglycerin for Heart Failure	235
9.3o	Nesiritide for Heart Failure	235
9.4	Management of Shock	235
9.5	Angina	236
9.5a	Pathophysiology of Angina	236



- 9.5b Pharmacologic Treatment of Angina 236
- 9.5c β -Blockers as Antianginals 236
- 9.5d Calcium Channel Blockers as Antianginals 238
- 9.5e Nitroglycerin as an Antianginal 239
- 9.5f Ranolazine 239
- 9.6 Acute Coronary Syndromes 240
 - 9.6a Myocardial Infarction 240
 - 9.6b Diabetes Mellitus 240
 - 9.6c Classes of Diabetes Drugs 241
 - 9.6d Lipid-Lowering Agents 242
- Summary** 244
- Review Questions** 244
- Case Study 9–1 An elderly female** 245

Chapter 10

Blood Pressure and Antithrombotic Agents 247

- 10.1 Blood Pressure 248
 - 10.1a The Basics 248
 - 10.1b Blood Vessels 249
 - 10.1c Regulation of Blood Pressure 250
 - 10.1d Hypertension 250
- 10.2 Categories of Drugs to Treat Hypertension 254
 - 10.2a Direct-Acting α_2 -Agonists or Central-Acting Sympatholytics 254
 - 10.2b α_1 -Blockers or Peripheral-Acting Sympatholytics 255
 - 10.2c β -Blockers 255
 - 10.2d Diuretics 256
 - 10.2e Angiotensin-Converting Enzyme Inhibitors (ACEIs) 259
 - 10.2f Angiotensin II Receptor Blockers (ARBs) 260
 - 10.2g Calcium Channel Blockers 261
 - 10.2h Vasodilators 261
 - 10.2i Agents for Hypertensive Emergencies/Urgencies 262
 - 10.2j Treating Hypotension 266
- 10.3 The Hemostatic System 266
 - 10.3a The Clotting Process 266

- 10.3b Anticoagulants 267
- 10.3c Direct Thrombin Inhibitors 270
- 10.3d Antiplatelet Drugs 271
- 10.3e Platelet Glycoprotein IIb/IIIa Receptor Inhibitors 273
- 10.3f Fibrinolytics 273

Summary 275

Review Questions 275

Case Study 10–1 Hypertensive emergency 276

Case Study 10–2 Antiplatelet therapy 276

Chapter 11

Neuromuscular, Sedative, Anesthetic, and Analgesic Agents 277

- 11.1 Nerve Transmission 279
 - 11.1a Physiology of Muscle Contraction 279
 - 11.1b Acetylcholinesterase 280
 - 11.1c Neuromuscular Blocking Agents 280
 - 11.1d Nondepolarizing Agents 281
 - 11.1e Depolarizing Agents 281
 - 11.1f NMBA Selection Factors 282
- 11.2 Skeletal Muscle Relaxants 285
- 11.3 Sedatives, Hypnotics, and Anxiolytics 286
 - 11.3a Terminology 286
 - 11.3b Benzodiazepines 286
 - 11.3c α_2 -Adrenergic Agonist (Sedative) 287
 - 11.3d Nonbenzodiazepines 287
 - 11.3e Barbiturates 287
 - 11.3f Conscious Sedation 288
- 11.4 Anesthetics 288
 - 11.4a General versus Local 288
 - 11.4b General Anesthesia 288
 - 11.4c Stages of Anesthesia 289
 - 11.4d Specific General Anesthetics 289
 - 11.4e Local Anesthetics 291
 - 11.4f Postoperative Nausea and Vomiting 292
- 11.5 Ventilatory Stimulants 293

- 11.6 Analgesia 294
 - 11.6a Principles of Analgesia 294
 - 11.6b The Pain Response 294
 - 11.6c Analgesics 295
 - 11.6d Outcomes Assessment
Analgesic Therapy 296
 - 11.6e Pain-Related Terminology 296
 - 11.6f Classes of Analgesics 297
 - 11.6g Opioids 297
 - 11.6h Opioid Antagonists 299
 - 11.6i Corticosteroids 300
 - 11.6j Nonsteroidal Anti-
inflammatory Agents 301
 - 11.6k Analgesic Synergy 302
 - 11.6l Adjuncts to Analgesics 303

Summary 305

Review Questions 305

Case Study 11–1 A 38-year-old man 306

Chapter 12

Therapeutic Medical Gases 307

- 12.1 Oxygen Therapy 308
 - 12.1a Physiologic Background 308
 - 12.1b Hypoxemia 309
 - 12.1c Clinical Manifestations
of Hypoxemia 311
 - 12.1d Hypoxia 311
 - 12.1e Goals of Oxygen Therapy 313
 - 12.1f Oxygen Administration
Devices 313
 - 12.1g Monitoring Oxygen Therapy 318
 - 12.1h Hazards of Oxygen Therapy 319
- 12.2 Helium Therapy 320
 - 12.2a Indications for Helium Therapy 320
 - 12.2b Administration of Helium-
Oxygen 321
 - 12.2c Hazard of Helium-
Oxygen Therapy 321
- 12.3 Nitric Oxide Therapy 321
 - 12.3a Physiology of Nitric Oxide 322
 - 12.3b iNO Administration
and Dosage 322
 - 12.3c Therapeutic Indications for
Inhalation of Nitric Oxide 323
 - 12.3d Monitoring Nitric Oxide
Therapy 323

Summary 324

Review Questions 324

Case Study 12–1 A 68-year-old woman 325

Part 3: Putting It All Together 327

Chapter 13

Pharmacologic Management of Asthma, Chronic Bronchitis, and Emphysema 329

- 13.1 Asthma 331
 - 13.1a Background 331
 - 13.1b Differential Diagnosis 332
 - 13.1c Asthma Symptoms 333
 - 13.1d Asthma Treatment Goals 335
 - 13.1e Classification of Asthma
Severity 336
 - 13.1f Asthma Medications 337
 - 13.1g Asthma Management 339
 - 13.1h Management of Acute
Asthma Exacerbations 341
- 13.2 COPD 345
 - 13.2a Background 345
 - 13.2b Etiology 345
 - 13.2c Prevention: The Key to
Treatment of COPD 347
 - 13.2d COPD Treatment Goals 352
 - 13.2e Assessment of COPD 352
 - 13.2f Drugs Used to Treat COPD 353
 - 13.2g Step-by-Step Approach 357

Summary 359

Review Questions 359

Case Study 13–1 A 25-year-old man 360

Case Study 13–2 A 60-year-old woman 361

Chapter 14

Pharmacologic Treatment of Respiratory Infectious Diseases 363

- 14.1 Developing a Therapeutic Plan for
Respiratory Infectious Diseases 365
 - 14.1a Empiric Treatment 365



14.1b Local Resistance Patterns (the Antibigram) 366	15.3b Epinephrine 406
14.1c Individualizing Therapy 367	15.3c Vasopressin 407
14.2 Upper Airway Infectious Diseases 369	15.3d Norepinephrine 407
14.2a Otitis Media 369	15.3e Sodium Bicarbonate 408
14.2b Sinusitis 372	15.4 Positive Inotropic Drugs 409
14.2c Pharyngitis 375	15.4a Digoxin 409
14.3 Other Upper Airway Infections 377	15.4b Milrinone 409
14.3a Epiglottitis 377	15.4c Dopamine 410
14.3b Croup 378	15.4d Dobutamine (Dobutrex®) 410
14.4 Lower Respiratory Tract Infections 379	15.5 Antiarrhythmic Drugs 411
14.4a Acute Bronchitis and Bronchiolitis 379	15.5a Atropine 411
14.4b Pneumonia 381	15.5b Amiodarone (Cordarone®) 412
14.4c Tuberculosis 388	15.5c Lidocaine 412
14.4d Avian Influenza 390	15.5d Procainamide (Pronestyl®) 413
14.4e COVID-19 390	15.5e Magnesium Sulfate 414
14.5 Chemical Terrorism 392	15.5f Ibutilide (Corvert®) 415
Summary 393	15.6 Calcium Channel Blockers 415
Review Questions 393	15.6a Verapamil (Calan®, Isoptin®) 415
Case Study 14–1 A 60-year-old man 394	15.6b Diltiazem (Cardizem®) 416
	15.6c Adenosine (Adenocard®) 416
	15.6d β -Adrenergic Blockers 417
	15.6e Sotalol (Betapace®) 418
	Review Questions 419
	Case Study 15–1 A 67-year-old woman 420

Chapter 15

Medications for

Emergency Cardiovascular

Life Support 395

15.1 Normal Conduction and Arrhythmias 397
15.1a Electrophysiology 397
15.1b Normal Conduction 398
15.1c Acute Myocardial Infarction 399
15.1d Bradycardia 400
15.1e Tachycardia 400
15.1f Ventricular Fibrillation 402
15.1g Asystole 403
15.1h Pulseless Electrical Activity 403
15.2 Pharmacologic Agents for Advanced Life Support 404
15.2a Medication Access 404
15.2b Categories of ACLS Drugs 404
15.3 Medications for Cardiovascular Support 405
15.3a Oxygen 405

Appendices 421

Glossary 425

Index 433